RU94022863A - HYBRID POLYPEPTIDE S 304, NS 304 DNA FRAGMENT, POLYPEPTIDE ANTI-VIRUS ACTIVITY - Google Patents

HYBRID POLYPEPTIDE S 304, NS 304 DNA FRAGMENT, POLYPEPTIDE ANTI-VIRUS ACTIVITY

Info

Publication number
RU94022863A
RU94022863A RU94022863/13A RU94022863A RU94022863A RU 94022863 A RU94022863 A RU 94022863A RU 94022863/13 A RU94022863/13 A RU 94022863/13A RU 94022863 A RU94022863 A RU 94022863A RU 94022863 A RU94022863 A RU 94022863A
Authority
RU
Russia
Prior art keywords
polypeptide
dna fragment
virus activity
hybrid
fragment
Prior art date
Application number
RU94022863/13A
Other languages
Russian (ru)
Other versions
RU2096458C1 (en
Inventor
А.В. Сидоров
А.Г. Здановский
В.В. Зверев
А.В. Пугач
В.В. Малюшова
Original Assignee
А.В. Сидоров
А.Г. Здановский
В.В. Зверев
А.В. Пугач
В.В. Малюшова
Filing date
Publication date
Application filed by А.В. Сидоров, А.Г. Здановский, В.В. Зверев, А.В. Пугач, В.В. Малюшова filed Critical А.В. Сидоров
Priority to RU94022863A priority Critical patent/RU2096458C1/en
Priority claimed from RU94022863A external-priority patent/RU2096458C1/en
Publication of RU94022863A publication Critical patent/RU94022863A/en
Application granted granted Critical
Publication of RU2096458C1 publication Critical patent/RU2096458C1/en

Links

Claims (1)

Сущность изобретения состоит в том, что получен гибридный полипептид S304, представляющий собой рецепторотоксин, в котором фрагмент CD4 рецептора является рецепторной, а фрагмент дифтерийного токсина - токсической частью. Искомый полипептид ингибирует цитопатическое действие вируса иммунодефицита человека 1 типа в системе in vitro.The essence of the invention is that a hybrid S304 polypeptide is obtained, which is a receptor toxin, in which the CD4 receptor fragment is a receptor fragment and the diphtheria toxin fragment is a toxic part. The desired polypeptide inhibits the cytopathic effect of human immunodeficiency virus type 1 in the in vitro system.
RU94022863A 1994-06-14 1994-06-14 Hybrid receptor-toxin s 304 and dna fragment ns 304 encoding hybrid receptor-toxin s 304 RU2096458C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU94022863A RU2096458C1 (en) 1994-06-14 1994-06-14 Hybrid receptor-toxin s 304 and dna fragment ns 304 encoding hybrid receptor-toxin s 304

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU94022863A RU2096458C1 (en) 1994-06-14 1994-06-14 Hybrid receptor-toxin s 304 and dna fragment ns 304 encoding hybrid receptor-toxin s 304

Publications (2)

Publication Number Publication Date
RU94022863A true RU94022863A (en) 1996-01-27
RU2096458C1 RU2096458C1 (en) 1997-11-20

Family

ID=20157287

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94022863A RU2096458C1 (en) 1994-06-14 1994-06-14 Hybrid receptor-toxin s 304 and dna fragment ns 304 encoding hybrid receptor-toxin s 304

Country Status (1)

Country Link
RU (1) RU2096458C1 (en)

Similar Documents

Publication Publication Date Title
ZA964694B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
FR2716893B1 (en) Recombinant viruses, their preparation and their therapeutic use.
DE69016956T2 (en) Recombinant turkey herpes virus and derived live vaccine vector.
FR2712603B1 (en) Recombinant viruses, preparation and use in gene therapy.
DK0595436T3 (en) PORCINT RESPIRATION AND REPRODUCTION DISEASE VIRUS, VACCINES AND VIRAL DNA
ATE264914T1 (en) ANTIVIRAL PROTEINS, DNA CODING THEREOF, AND USE THEREOF
EP0831873A4 (en) The treatment of hiv and other viral infections using combinatory therapy
CY1106152T1 (en) NEW ANTI-HIV IMMUNE (ANTITOXINS), PREPARATION METHODS AND APPLICATION IN THE PREVENTION AND TREATMENT OF AIDS
TR199801418T2 (en) Recombinant to weightlifting kar���m�.
FR2718150B1 (en) Recombinant viruses, preparation and use in gene therapy.
ZA964680B (en) Recombinant feline immunodeficiency vaccines produced in baculovirus and their use against feline immunodeficiency virus infection.
NO912825L (en) PROCEDURE FOR THE PREPARATION OF COCONJUGATE VACCINES INCLUDING IM MUNOGENT PROTEIN, HIV RELATED PEPTIDES AND ANIONIC GROUPS.
CA2192512A1 (en) Nm03 antibody materials and methods
MX9202781A (en) VACCINE AND TREATMENT METHOD FOR HUMAN IMMUNODEFICIENCY VIRUSES.
DE69101683T2 (en) Recombinant Mareks disease virus.
EP0631506A4 (en) Selectively deglycosylated human immunodeficiency virus type 1 envelope vaccines.
KR970702919A (en) Recombinant Human Immunodeficiency Virus Vector and Process for Producing the same
FR2712602B1 (en) Recombinant viruses, preparation and use in gene therapy.
FI101797B1 (en) STLV-III virus related polypeptides, diagnostic systems, and assay methods
ITVR940096A0 (en) PROCEDURE AND EQUIPMENT FOR THE SPECIFIC IMMUNADORPTION OF HIV VIRUS, GP120 ANTIGEN AND CD4-GP120 COMPLEX.
RU94022863A (en) HYBRID POLYPEPTIDE S 304, NS 304 DNA FRAGMENT, POLYPEPTIDE ANTI-VIRUS ACTIVITY
DE69213325D1 (en) Immune preparation directed against the human immunodeficiency virus
FR2717495B1 (en) Recombinant viruses, preparation and use in gene therapy.
CA2163212A1 (en) Therapeutic compounds
ATE236195T1 (en) DETOXIFICATION OF PHARMACEUTICAL ACTIVE INGREDIENTS USING CYCLODEXTRIN OLIGOMERS